Synthesis and Study of Natural and Non-natural Antiproliferative Agents

天然和非天然抗增殖剂的合成与研究

基本信息

  • 批准号:
    8322894
  • 负责人:
  • 金额:
    $ 4.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1988
  • 资助国家:
    美国
  • 起止时间:
    1988-04-01 至 2014-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our laboratory is developing practical synthetic routes to families of chemically complex natural products that have been shown to inhibit the growth of human cancer cells. In this way, we are able to prepare large numbers of related structures (analogs) for evaluation as new chemotherapeutic agents, compounds with potentially improved properties that would be otherwise unavailable for study. The synthetic routes we are developing also allow us to prepare chemical probes that are useful for the identification of the cellular targets of the natural products families we study, which in many cases are not known. The dual impacts of this work, providing molecules for target binding and target identification, are of potentially great potential utility in the extraordinarily challenging problem of developing new cancer therapies. Indeed, many of our current front-line small-molecule therapies for cancer are natural products or were derived from natural products lead structures, and many important targets of cancer have been identified through the use of probes prepared by chemical modification of natural products. Among the classes of natural products we are studying are the cortistatins, a family of steroidal alkaloids isolated from a marine sponge that potently inhibit the proliferation of human umbilical vein endothelial cells; the daphniglaucins, unique plant-derived substances that have been shown to inhibit the growth of a lymphoma-derived cell line; the trioxacarcins, bacterial fermentation products with extremely potent inhibitory properties toward growing cancer cells and known to alkylate duplex DNA; salinosporamides, isolates from a marine bacterium that target the proteasome (also targeted by Velcade(R), an approved chemotherapeutic agent for multiple myeloma), and avrainvillamides, fungal natural products shown in our laboratory to target nucleophosmin, a protein whose mutation has been implicated in ~35% of all acute myelogenous lukemias (AMLs) and a novel target for chemotherapeutic intervention.
描述(由申请人提供):我们的实验室正在开发化学复杂天然产物家族的实用合成路线,这些天然产物已被证明可以抑制人类癌细胞的生长。通过这种方式,我们能够制备大量的相关结构(类似物),用于作为新的化疗药物进行评估,这些化合物具有潜在的改善性质,否则将无法用于研究。我们正在开发的合成路线也使我们能够制备化学探针,用于识别我们研究的天然产物家族的细胞靶点,在许多情况下,这些靶点是未知的。这项工作的双重影响,提供分子的目标结合和目标识别,是潜在的巨大的潜在效用,在非常具有挑战性的问题,开发新的癌症疗法。事实上,我们目前用于癌症的许多一线小分子疗法是天然产物或源自天然产物的先导结构,并且通过使用通过天然产物的化学修饰制备的探针已经鉴定了癌症的许多重要靶标。我们正在研究的天然产物类别包括:皮质抑素,一种从海绵中分离的甾体生物碱家族,可有效抑制人脐静脉内皮细胞的增殖;瑞香素,一种独特的植物衍生物质,已被证明可抑制淋巴瘤衍生细胞系的生长; trioxacarcins,细菌发酵产物,对生长的癌细胞具有极强的抑制特性,并且已知可烷基化双链体DNA; salinosporamides,从海洋细菌中分离出来,(也被Velcade(R)靶向,Velcade(R)是一种批准的用于多发性骨髓瘤的化疗剂),和avrainvillamides,我们实验室中显示的靶向核磷蛋白的真菌天然产物,一种蛋白质,其突变与约35%的急性髓细胞性白血病(AML)有关,是化疗干预的新靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW G MYERS其他文献

ANDREW G MYERS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW G MYERS', 18)}}的其他基金

Discovery through chemical synthesis of antibiotics effective against modern bacterial pathogens
通过化学合成发现对现代细菌病原体有效的抗生素
  • 批准号:
    10570180
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
Discovery through chemical synthesis of antibiotics effective against modern bacterial pathogens
通过化学合成发现对现代细菌病原体有效的抗生素
  • 批准号:
    10419458
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
Synthesis of Antibiotics
抗生素的合成
  • 批准号:
    8298364
  • 财政年份:
    2011
  • 资助金额:
    $ 4.71万
  • 项目类别:
Synthesis of Antibiotics
抗生素的合成
  • 批准号:
    7037200
  • 财政年份:
    2001
  • 资助金额:
    $ 4.71万
  • 项目类别:
Synthesis of Antibiotics
抗生素的合成
  • 批准号:
    7538338
  • 财政年份:
    2001
  • 资助金额:
    $ 4.71万
  • 项目类别:
A PRACTICAL SYNTHETIC ROUTE TO THE TETRACYCLINES
四环素类药物的实用合成路线
  • 批准号:
    6835644
  • 财政年份:
    2001
  • 资助金额:
    $ 4.71万
  • 项目类别:
A PRACTICAL SYNTHETIC ROUTE TO THE TETRACYCLINES
四环素类药物的实用合成路线
  • 批准号:
    6626402
  • 财政年份:
    2001
  • 资助金额:
    $ 4.71万
  • 项目类别:
A PRACTICAL SYNTHETIC ROUTE TO THE TETRACYCLINES
四环素类药物的实用合成路线
  • 批准号:
    6893948
  • 财政年份:
    2001
  • 资助金额:
    $ 4.71万
  • 项目类别:
A PRACTICAL SYNTHETIC ROUTE TO THE TETRACYCLINES
四环素类药物的实用合成路线
  • 批准号:
    6692976
  • 财政年份:
    2001
  • 资助金额:
    $ 4.71万
  • 项目类别:
Synthesis of Antibiotics
抗生素的合成
  • 批准号:
    7154759
  • 财政年份:
    2001
  • 资助金额:
    $ 4.71万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了